ACTERO LAUNCHES DOXORUBICIN ACTE AND ETOPOSIDE ACTE

April 15, 2018

Author: Acteropharma

Actero Middle East is pleased to announce the launch of two new molecules to the Iranian market. Doxorubicin ACTe 10 mg and 50 mg and Etoposide ACTe 100 mg/5ml. Doxorubicin ACTe 10mg and 50mg injections are the generic version of Adriamycin, a chemotherapy medication used to treat a broad range of cancers including breast cancer, bladder cancer, Kaposi’s sarcoma, lymphoma, and acute lymphocytic leukemia. Etoposide ACTe 100 mg/5ml injections are the generic version of Etopophos, a chemotherapy medication used to treat a broad range of cancers including testicular cancer, lung cancer, lymphoma, leukemia, neuroblastoma, and ovarian cancer.

“Doxorubicin ACTe and Etoposide ACTe are the two latest products in our growing oncology portfolio. With these new additions, we aim to gain the trust of all stakeholders and continue building a portfolio where every Actero medicine stands for reliability.”

CEO of Actero

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

Last News

رویداد آگاهی از سرطان پستان
November 3, 2026

Author:

Acteropharma
According to Actover Group’s Public Relations Department, the event brought together participants, physicians and pharmacists from across the Group to highlight the importance of early detection and timely treatment of breast cancer. Attendees also received information about breast cancer risk factors, warning signs, self-examination and diagnostic methods.
روز کارگر-EN-08
May 1, 2025

Author:

Acteropharma
International Labor Day is a global tribute to the unwavering will and tireless hands that shape the future. It is a meaningful occasion to honor those whose dedication, expertise, and commitment drive the engines of progress and prosperity.
the 9th International Radio-Oncology Congress
March 11, 2025

Author:

Acteropharma
From January 30 to February 1, the 9th International Radio-Oncology Congress was held with the aim of advancing scientific programs in the community and supporting the expansion of cancer research.